BioCryst Pharmaceuticals Inc. reported third quarter 2025 financial results with ORLADEYO net revenue of $159.1 million, a 37 percent increase year-over-year. The company posted an operating profit of $29.6 million, up 285 percent from the previous year, and a non-GAAP operating profit of $51.7 million, a 107 percent year-over-year rise. BioCryst raised its full-year 2025 ORLADEYO revenue guidance to between $590 million and $600 million and lowered its full-year non-GAAP operating expense guidance to between $430 million and $440 million. The company completed the sale of its European ORLADEYO business, using the proceeds to retire all remaining Pharmakon term debt. BioCryst also signed a definitive agreement to acquire Astria Therapeutics, with the transaction expected to close in the first quarter of 2026. Research and development expenses for the third quarter increased to $44.6 million, primarily due to the advancement of BCX17725 and pre-clinical program activities.